This guide explains best biotech stocks to in plain words. Best biotech stocks is what many readers search for, so this guide gets straight to it. Biotech can change lives and change portfolios, up or down. One trial result can double a stock or cut it in half. The edge is knowing what you are buying.

What to look for in the best biotech stocks
Large biotechs earn money from approved drugs. Small ones depend on trials. Treat them very differently.
- Approved drug sales and patent life.
- Pipeline depth: more shots on goal reduce risk.
- Cash runway for smaller companies.
Biotech companies to study
These are companies many investors study in this area. Being on a list is not a recommendation. Open each profile, read the filings and make up your own mind.
- Moderna (MRNA): develops medicines and vaccines using messenger RNA
- BioNTech (BNTX): develops vaccines and cancer treatments
- Regeneron (REGN): sells antibody medicines for eye disease and other conditions
- Vertex Pharmaceuticals (VRTX): sells treatments for cystic fibrosis and is expanding into other diseases
- Gilead Sciences (GILD): sells medicines for HIV and liver disease
- Amgen (AMGN): sells a wide range of biologic medicines
The risks to respect
- Failed trials can erase value quickly.
- Patent expirations cut sales.
- Small companies can run out of cash.
Put it to work
Start with the free Investing From Zero book series if the basics are new. Then test yourself with the Spot the Red Flag game and the Read the Filing game. Run numbers in our free calculators, browse the whole field in StockVert, or search all 3,000 plus company profiles in the company directory. Get one clear email a week in the free weekly brief.
Questions people ask
Are biotech stocks too risky?
Single trial results can swing small companies sharply. Larger firms with many products carry less of that risk.
How do I research a biotech?
Read the pipeline section, trial stages and cash position in the annual report.
Facts about any company can be checked free on SEC EDGAR. This article is for education only. It is not investment advice and not an offer to buy or sell any security. Companies named were chosen as examples for study. Do your own research and consider talking to a licensed adviser. Positive Stocks has no position in the companies named and was not paid to mention them.
How a drug gets from idea to shelf
Biotech companies often earn nothing until a medicine is approved, so it helps to know the path. First comes lab and animal testing. Then phase 1 trials check safety in a small group. Phase 2 checks whether it seems to work. Phase 3 tests it in a large group against a standard treatment or a placebo. After that the company asks a regulator, such as the FDA in the United States, for approval. Many drugs fail along the way, and each step takes time and cash.
Cash runway, the number to find first
Runway is how many months the company can keep going at its current spending. Find cash in the latest quarterly report and divide it by the yearly cash burn. If runway is short, the company may need to sell new shares, which can lower the value of the shares already out there. That is not always bad, but you should know it is coming.
How to read a pipeline table
- Stage. Later stages have survived more tests.
- Condition. A medicine for a large group of patients can earn more, but faces more rivals.
- Partners. A big drug maker helping with a trial can be a good sign, because they check the work.
- Dates. Companies often list when they expect trial results. Those dates are events to know about.
A twenty minute research routine
- Read the company description and name its lead drug.
- Find the stage of that drug.
- Find cash and yearly burn, then work out runway.
- Read the risk section of the latest annual report.
- Write down one thing that would make you change your mind.
Questions people ask
Why do biotech stocks jump or fall so hard on news
Because one trial result can change what the whole company is worth. That is why position size matters.
Is a big biotech safer than a small one
Often it has more income and more drugs, so one failure matters less. Safer is not the same as safe.
This is education, not financial advice, and not a list of picks. Use the glossary for new terms.
